Quixin®
Levofloxacin 0.5%, 1.5% · ophthalmic solution
Antibiotic
Approved uses
Bacterial conjunctivitis (0.5%)
0.5%: Days 1 and 2, 1 to 2 drops q2h while awake, up to 8 times a day. Days 3 to 7, 1 to 2 drops q4h while awake, up to 4 times a day.
Bacterial corneal ulcer (1.5%)
1.5%: Days 1 to 3, 1 to 2 drops q30min to q2h while awake, plus doses about 4 and 6 hours after retiring. Day 4 to completion, 1 to 2 drops q1h to q4h while awake.
A single two-drop dose keeps tear levels above the MIC90 for 24 hours in healthy volunteers.
Contraindications
History of hypersensitivity to levofloxacin, to other quinolones, or to any component of this product.
Levofloxacin ophthalmic solution 0.5%, 5 mL bottle; levofloxacin ophthalmic solution 1.5%, 5 mL bottle
Fluoroquinolone, the L-isomer of ofloxacin, with in vitro activity against a wide range of gram-positive and gram-negative organisms; inhibits bacterial topoisomerase IV and DNA gyrase, the type II topoisomerases required for DNA replication, transcription, repair and recombination, and is often bactericidal at concentrations equal to or slightly above inhibitory concentrations. Structure and mode of action differ from beta-lactams and aminoglycosides, so activity may persist against organisms resistant to those classes; spontaneous in vitro resistance is rare (frequency 10^-9 to 10^-10).
Warnings & Precautions
- Hypersensitivity reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported with systemically administered quinolones, including levofloxacin, some following the first dose and some with cardiovascular collapse, loss of consciousness, angioedema, airway obstruction, dyspnea, urticaria and itching. If allergic reaction occurs, discontinue the drug. Serious acute reactions may require immediate emergency treatment, with oxygen and airway management as clinically indicated.
- Growth of resistant organisms with prolonged use: Prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, examine the patient with the aid of magnification, such as slit-lamp biomicroscopy, and where appropriate, fluorescein staining.
- Avoidance of contact lens wear: Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis.
Common Side Effects
Transient decreased vision, fever, foreign body sensation, headache, transient ocular burning, ocular pain or discomfort, pharyngitis, and photophobia were the most frequently reported reactions in the overall study population, occurring in approximately 1 to 3% of patients. Other reported reactions occurring in less than 1% of patients included allergic reactions, lid edema, ocular dryness, and ocular itching.
Pregnancy: Oral doses of 810 mg/kg/day in rats caused decreased fetal body weight and increased fetal mortality. No teratogenic effect was observed when rabbits were dosed orally as high as 50 mg/kg/day (systemic exposure approximately 2,250 times that at the maximum recommended human ophthalmic dose) or intravenously as high as 25 mg/kg/day (approximately 1000 times). There are no adequate and well-controlled studies in pregnant women; use during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: Levofloxacin has not been measured in human milk, but based upon data from ofloxacin it can be presumed to be excreted in human milk. Caution should be exercised when it is administered to a nursing mother.
Safety and effectiveness below age 6 years have not been established.